← 返回

肿瘤血液学免疫治疗进展:单克隆抗体与 CAR-T 细胞疗法

英文原题:Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.

查看英文原题

Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.

PubMed 2026/08/10(内容时间) Cells Q2 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫治疗在血液肿瘤学中的作用已得到充分确立。近年来,单克隆抗体取得了实质性发展,靶向广泛的分子(包括表面抗原、免疫检查点和细胞因子),并在多种血液系统恶性肿瘤(包括白血病、淋巴瘤和骨髓瘤)中展现出临床实用性。先进治疗药品(ATMPs),特别是嵌合抗原受体(CAR)T细胞的出现,提供了一种额外且有前景的治疗选择。这一快速发展的领域持续拓展治疗可能性。本文献综述的目的是总结血液肿瘤学中的新型免疫治疗策略,包括基于单克隆抗体和CAR-T 细胞的方法,并回顾近期临床试验的关键发现。

展开英文摘要原文

The role of immunotherapy in oncohematology is well established. Monoclonal antibodies have undergone substantial development in recent years, targeting a wide range of molecules (including surface antigens, immune checkpoints, and cytokines) and have demonstrated clinical utility across various hematologic malignancies, including leukemias, lymphomas, and myelomas.

The emergence of advanced therapy medicinal products (ATMPs), particularly chimeric antigen receptor (CAR) T cells, has provided an additional and promising therapeutic option. This rapidly evolving field continues to expand therapeutic possibilities. The objective of this literature review is to summarize novel immunotherapeutic strategies in oncohematology, including monoclonal antibody- and CAR T-cell-based approaches, and to review the key findings from recent clinical trials.

论文信息

作者
Mathias F、Fersing C、Bourgarel V、Gabert J、Peyron F
第一作者单位
CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Aix-Marseille University, 13005 Marseille, France.France
通讯作者单位
Pharmacy Department, Marseille Nord University Hospital Pharmacy, Assistance Publique-Hôpitaux de Marseille, 13015 Marseille, France.France
文献类型
综述
期刊
Cells2026 Aug 10
原文标识
PubMed 42645167 · DOI 10.3390/cells15161439